Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 06 June 2016 | By Zachary Brennan
It’s well known that competition among pharmaceutical companies is fierce, and a misstep, usually in a clinical trial, can result in millions, if not billions of dollars lost. And now a glimpse of that competition is boiling over into the realm of television advertising.
In a case from April, made public by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday, Boehringer Ingelheim called on the MHRA to pull a television advertisement for Reckitt Benckiser’s over-the-counter (OTC) laxative Senokot (BI offers a competing OTC laxative known as Dulcolax) as it appeared to suggest the active ingredient in the drug was natural.
“We considered that the advertisement suggested that Senokot’s efficacy was due to the fact that its active ingredient was natural. In August 2014 MHRA upheld a complaint about a similar advertisement for Senokot that also suggested its efficacy was due to it being natural,” MHRA said.
Reckitt Benckiser has since withdrawn the advertisement (a 2012 version can be seen on YouTube), and MHRA warned the company that it “could be required to submit all promotional material for vetting should a similar advertisement be published in future.”
Meanwhile, from 1997 to 2014, Boehringer has been advertising its Dulcolax laxative on television as a “gentle” alternative. And the fight over the laxative advertising market seems to be getting even more competitive as just four days ago, Boehringer published two YouTube videos asking people on UK streets if they’re embarrassed “talking about poo.”
Unlike in the US, pharmaceutical companies in the UK can only advertise over-the-counter medicines licensed by the MHRA or the European Commission to the general public, while prescription medicines cannot be advertised to the general public, though companies can promote them to health professionals and others who prescribe or supply pharmaceuticals.
MHRA Decision: Promotion of Senokot by Reckitt Benckiser
Tags: Senokot, Reckitt Benckiser, Boehringer Ingelheim, Dulcolax, laxative, OTC drug television advertisements
Regulatory Focus newsletters
All the biggest regulatory news and happenings.